

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 February 2025 (27.02.2025)



(10) International Publication Number
WO 2025/043172 A1

(51) International Patent Classification:

C07K 14/705 (2006.01) C07K 14/725 (2006.01)
A61K 38/17 (2006.01) C12N 15/62 (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2024/043615

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:

23 August 2024 (23.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/534,134 23 August 2023 (23.08.2023) US
63/534,136 23 August 2023 (23.08.2023) US

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(71) Applicant: SANA BIOTECHNOLOGY, INC. [US/US];
188 East Blaine Street, Suite 400, Seattle, Washington
98102 (US).

(72) Inventors: JOHNSON, Adam James; c/o Sana Biotech-
nology, Inc., 188 East Blaine Street, Suite 400, Seattle,
Washington 98102 (US). MCALISTER, Andrew Patrick;
c/o Sana Biotechnology, Inc., 188 East Blaine Street, Suite
400, Seattle, Washington 98102 (US). KIPNISS, Nathan
Hilton; c/o Sana Biotechnology, Inc., 188 East Blaine
Street, Suite 400, Seattle, Washington 98102 (US). DOW-
DLE, William; c/o Sana Biotechnology, Inc., 188 East
Blaine Street, Suite 400, Seattle, Washington 98102 (US).

(74) Agent: MURRAY, Shanna K. et al.; Choate, Hall & Ste-
wart LLP, Two International Place, Boston, Massachusetts
02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: MODIFIED CD47 PROTEINS AND THEIR USES

(57) Abstract: The present disclosure provides engineered CD47 proteins and uses thereof. Also disclosed are polynucleotides encoding the engineered CD47 protein, vectors comprising the polynucleotides, cells comprising the engineered proteins and/or the vectors, and compositions comprising the engineered CD47 protein.

WO 2025/043172 A1